Wednesday, August 8, 2012
Celsion Corp., of Lawrenceville, N.J., and Royal Philips Electronics, of Andover, Mass., said the FDA approved a Phase II study supporting a joint development program for ThermoDox, Celsion's heat-activated liposomal encapsulation of doxorubicin, in combination with Philips' Sonalleve MR-HIFU (MR-guided high intensity-focused ultrasound) technology for the palliation of painful bone metastases caused by lung, prostate or breast cancers.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.